| Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway S Herbertz, JS Sawyer, AJ Stauber, I Gueorguieva, KE Driscoll, ST Estrem, ... Drug design, development and therapy 9, 4479, 2015 | 541 | 2015 |
| Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in … RB Holmgaard, DA Schaer, Y Li, SP Castaneda, MY Murphy, X Xu, I Inigo, ... Journal for immunotherapy of cancer 6, 1-15, 2018 | 270 | 2018 |
| Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer D Melisi, R Garcia-Carbonero, T Macarulla, D Pezet, G Deplanque, ... British journal of cancer 119 (10), 1208-1214, 2018 | 232 | 2018 |
| Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma L Goyal, F Meric-Bernstam, A Hollebecque, JW Valle, C Morizane, ... New England Journal of Medicine 388 (3), 228-239, 2023 | 230 | 2023 |
| A phase 2 study of galunisertib (TGF-β1 receptor type I inhibitor) and sorafenib in patients with advanced hepatocellular carcinoma RK Kelley, E Gane, E Assenat, J Siebler, PR Galle, P Merle, IO Hourmand, ... Clinical and translational gastroenterology 10 (7), e00056, 2019 | 172 | 2019 |
| Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations: A Phase I Dose-Expansion Study F Meric-Bernstam, R Bahleda, C Hierro, M Sanson, J Bridgewater, ... Cancer discovery 12 (2), 402-415, 2022 | 159 | 2022 |
| Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor JM Yingling, WT McMillen, L Yan, H Huang, JS Sawyer, J Graff, ... Oncotarget 9 (6), 6659, 2018 | 147 | 2018 |
| Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1–4 inhibitor in patients with advanced solid tumors R Bahleda, F Meric-Bernstam, L Goyal, B Tran, Y He, I Yamamiya, ... Annals of Oncology 31 (10), 1405-1412, 2020 | 127 | 2020 |
| Trifluridine–tipiracil and bevacizumab in refractory metastatic colorectal cancer GW Prager, J Taieb, M Fakih, F Ciardiello, E Van Cutsem, E Elez, ... New England Journal of Medicine 388 (18), 1657-1667, 2023 | 125 | 2023 |
| First-in-human study of LY3039478, an Oral Notch signaling inhibitor in advanced or metastatic cancer C Massard, A Azaro, JC Soria, U Lassen, C Le Tourneau, D Sarker, ... Annals of Oncology 29 (9), 1911-1917, 2018 | 125 | 2018 |
| Effects of TGF-beta signalling inhibition with galunisertib (LY2157299) in hepatocellular carcinoma models and in ex vivo whole tumor tissue samples from patients M Serova, A Tijeras-Raballand, C Dos Santos, M Albuquerque, V Paradis, ... Oncotarget 6 (25), 21614, 2015 | 116 | 2015 |
| Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer D Melisi, DY Oh, A Hollebecque, E Calvo, A Varghese, E Borazanci, ... Journal for Immunotherapy of Cancer 9 (3), 2021 | 115 | 2021 |
| Novel transforming growth factor beta receptor I kinase inhibitor galunisertib (LY2157299) in advanced hepatocellular carcinoma S Faivre, A Santoro, RK Kelley, E Gane, CE Costentin, I Gueorguieva, ... Liver International 39 (8), 1468-1477, 2019 | 108 | 2019 |
| A first-in-human phase I study of the oral Notch inhibitor, LY900009, in patients with advanced cancer S Pant, SF Jones, CD Kurkjian, JR Infante, KN Moore, HA Burris, ... European Journal of Cancer 56, 1-9, 2016 | 99 | 2016 |
| Preclinical and clinical development of novel agents that target the protein kinase C family M Serova, A Ghoul, KA Benhadji, E Cvitkovic, S Faivre, F Calvo, F Lokiec, ... Seminars in oncology 33 (4), 466-478, 2006 | 96 | 2006 |
| A Phase I Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic Cancer RJ Sullivan, A Hollebecque, KT Flaherty, GI Shapiro, JR Ahnert, ... Molecular cancer therapeutics 19 (2), 460-467, 2020 | 80 | 2020 |
| TGFβ receptor inhibitor galunisertib is linked to inflammation-and remodeling-related proteins in patients with pancreatic cancer D Melisi, R Garcia-Carbonero, T Macarulla, D Pezet, G Deplanque, ... Cancer chemotherapy and pharmacology 83, 975-991, 2019 | 80 | 2019 |
| Effects of protein kinase C modulation by PEP005, a novel ingenol angelate, on mitogen-activated protein kinase and phosphatidylinositol 3-kinase signaling in cancer cells M Serova, A Ghoul, KA Benhadji, S Faivre, C Le Tourneau, E Cvitkovic, ... Molecular cancer therapeutics 7 (4), 915-922, 2008 | 78 | 2008 |
| FOENIX-CCA2: A phase II, open-label, multicenter study of futibatinib in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 gene fusions … L Goyal, F Meric-Bernstam, A Hollebecque, JW Valle, C Morizane, ... Journal of Clinical Oncology 38 (15_suppl), 108-108, 2020 | 75 | 2020 |
| A phase 2 study of a novel transforming growth factor-beta (TGF-β1) receptor I kinase inhibitor, LY2157299 monohydrate (LY), in patients with advanced hepatocellular carcinoma … SJ Faivre, A Santoro, RK Kelley, P Merle, E Gane, JY Douillard, ... Journal of Clinical Oncology 32 (3_suppl), LBA173-LBA173, 2014 | 66 | 2014 |
Antoine HollebecqueConsultant, Gustave Roussy Cancer Campus, Villejuif在 gustaveroussy.fr 的电子邮件经过验证
